Capricor’s DMD clinical trial meets primary endpoints; Delaware court rules against Takeda in Lupron feud

Beverly Hills, CA-based biotech Capricor Therapeutics revealed today final data from its clinical trial evaluating stem cell therapy CAP-1002 for patients in advanced stages of Duchenne muscular dystrophy.

Duchenne is a rare muscle-wasting disease caused by the absence of dystrophin, a protein that helps...

Click to view original post